Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ecto-NOX disulfide-thiol exchanger 2 (ENOX2) is a potential prognostic marker for malignant melanoma. High ENOX2 expression correlates with poorer survival and increased cancer progression, suggesting it as a therapeutic target.
Area Of Science
- Oncology
- Biochemistry
- Cancer Biology
Background
- Malignant melanoma incidence is rising, necessitating novel prognostic biomarkers.
- Ecto-NOX disulfide-thiol exchanger 2 (ENOX2/tNOX) is a protein linked to cancer and growth.
- Understanding ENOX2's role is crucial for melanoma prognosis and therapy.
Purpose Of The Study
- To evaluate ecto-NOX disulfide-thiol exchanger 2 (ENOX2) as a prognostic biomarker in primary malignant melanoma.
- To investigate the therapeutic potential of targeting ENOX2 in melanoma.
Main Methods
- Tissue microarray analysis of immunohistochemical ENOX2 protein expression.
- Analysis of TCGA ENOX2 RNA expression data.
- Melanoma cell line viability assays and Western blots with ENOX2 inhibitor phenoxodiol (PXD) and vemurafenib.
Main Results
- High ENOX2 expression is linked to decreased overall, disease-specific, and metastasis-free survival.
- ENOX2 expression increases with malignancy, tumor thickness, and stage.
- Phenoxodiol (PXD) inhibited melanoma cell viability and may prevent BRAF inhibitor resistance.
Conclusions
- ENOX2 is a potential prognostic marker for malignant melanoma.
- ENOX2 plays a role in melanoma growth, progression, and metastasis.
- Targeting ENOX2 offers a potential therapeutic strategy for melanoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
